NextCure (NXTC) SVP awarded 8,270 employee stock options at $10.85

Rhea-AI Filing Summary

NextCure, Inc. reported that Senior Vice President of Development and Manufacturing Sourav K. Kundu received an employee stock option grant. On January 30, 2026, he was awarded options to buy 8,270 shares of common stock at an exercise price of $10.85 per share.

One fourth of the option vests on January 30, 2027, with the remaining portion vesting in 36 monthly installments beginning February 28, 2027. Following this grant, Kundu beneficially owns 8,270 stock options, all held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kundu Sourav

(Last) (First) (Middle)

C/O NEXTCURE, INC.

9000 VIRGINIA MANOR ROAD, SUITE 200

(Street)

BELTSVILLE MD 20705

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NextCure, Inc. [ NXTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr VP, Dev. & Mfg.

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$10.85	01/30/2026		A		8,270		(1)	01/29/2036	Common Stock	8,270	$0	8,270	D

Explanation of Responses:

1. One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.

	/s/ Steven P. Cobourn, as attorney-in-fact for Sourav K. Kundu	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NextCure (NXTC) report for Sourav K. Kundu?

Sourav K. Kundu, Senior Vice President of Development and Manufacturing at NextCure, received an employee stock option grant. On January 30, 2026, he was awarded options for 8,270 shares of common stock at an exercise price of $10.85 per share.

How many NextCure (NXTC) stock options were granted in this Form 4 filing?

The Form 4 shows an award of 8,270 employee stock options to Sourav K. Kundu. These options give him the right to buy 8,270 shares of NextCure common stock at an exercise price of $10.85 per share, subject to the vesting schedule.

What is the vesting schedule for Sourav K. Kundu’s NextCure (NXTC) stock options?

One fourth of Sourav K. Kundu’s option grant vests on January 30, 2027. The remaining portion vests in 36 monthly installments beginning on February 28, 2027, creating a multi-year vesting period tied to continued service.

What is the exercise price of the employee stock options reported for NextCure (NXTC)?

The employee stock options granted to Sourav K. Kundu have an exercise price of $10.85 per share. This means he can purchase NextCure common stock at $10.85 per share once the options have vested and are exercisable under the grant terms.

How many NextCure (NXTC) derivative securities does Sourav K. Kundu own after this transaction?

After the reported grant, Sourav K. Kundu beneficially owns 8,270 derivative securities in the form of employee stock options. All 8,270 options are reported as held directly, reflecting his ownership position following this transaction.

Is the reported NextCure (NXTC) Form 4 transaction a purchase or a grant?

The reported Form 4 transaction is an employee stock option grant, coded as an acquisition ("A") of derivative securities. The options were granted at a $10.85 exercise price, with no cash price per option at the time of grant.